Genomic profiling identifies actionable DNA-repair defects in a new cervical cancer model

Area of Science:

• Oncology
• Genetics
• Molecular Biology

Background:

• Cervical cancer treatment often faces challenges due to tumor heterogeneity.
• Understanding the genetic landscape of HPV-negative cervical cancer is crucial for developing targeted therapies.

Purpose of the Study:

• To genetically profile a novel HPV-negative cervical cancer model.
• To identify actionable targets and therapeutic sensitivities.

Main Methods:

• Genetic profiling of a new cervical cancer model.
• Assessment of sensitivity to PARP inhibitors (olaparib) and platinum-based chemotherapeutics.
• Comparison with BRCA1/2-proficient cells.

Main Results:

• Identified pathogenic variants in oncogenic signaling, cell cycle, and DNA repair pathways (homologous recombination, non-homologous end-joining, mismatch repair).
• Found deficiencies in BRCA2, RAD51, and MLH1 as actionable targets.
• Demonstrated sensitivity of the model to olaparib, enhanced by combination therapy.
• Observed resistance in BRCA1/2-proficient cells.

Conclusions:

• In-depth genetic analysis can uncover susceptibilities in cervical cancer.
• Targeting DNA repair deficiencies with PARP inhibitors and chemotherapy offers a personalized medicine strategy.
• This model provides a platform for evaluating novel therapeutic combinations.